Palvella Therapeutics (PVLA) Net Income towards Common Stockholders (2016 - 2024)
Historic Net Income towards Common Stockholders for Palvella Therapeutics (PVLA) over the last 12 years, with Q4 2024 value amounting to -$3.4 million.
- Palvella Therapeutics' Net Income towards Common Stockholders fell 12434.07% to -$3.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$17.4 million, marking a year-over-year decrease of 7402.68%. This contributed to the annual value of -$17.4 million for FY2024, which is 19731.51% down from last year.
- According to the latest figures from Q4 2024, Palvella Therapeutics' Net Income towards Common Stockholders is -$3.4 million, which was down 12434.07% from -$7.0 million recorded in Q3 2024.
- Over the past 5 years, Palvella Therapeutics' Net Income towards Common Stockholders peaked at $13.8 million during Q4 2023, and registered a low of -$19.0 million during Q3 2021.
- Moreover, its 5-year median value for Net Income towards Common Stockholders was -$9.2 million (2021), whereas its average is -$7.8 million.
- Per our database at Business Quant, Palvella Therapeutics' Net Income towards Common Stockholders plummeted by 150869.0% in 2020 and then skyrocketed by 22393.45% in 2023.
- Over the past 5 years, Palvella Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$12.4 million in 2020, then rose by 11.27% to -$11.0 million in 2021, then decreased by 1.48% to -$11.2 million in 2022, then surged by 223.93% to $13.8 million in 2023, then plummeted by 124.34% to -$3.4 million in 2024.
- Its last three reported values are -$3.4 million in Q4 2024, -$7.0 million for Q3 2024, and -$4.4 million during Q2 2024.